跳到內容

腫瘤科

貧血的管理

紅細胞生成刺激劑

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. （開啟新視窗）

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

來源‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

檢索‎: PubMed 29471514

DOI碼‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 （開啟新視窗）

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. （開啟新視窗）

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

來源‎: Acta Haematol 2007;117(3):162-7.

檢索‎: PubMed 17148935

DOI碼‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 （開啟新視窗）

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. （開啟新視窗）

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

來源‎: Am J Hematol 2013;88(12):990-6.

檢索‎: PubMed 23873823

DOI碼‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 （開啟新視窗）

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. （開啟新視窗）

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

來源‎: J Clin Oncol 2011;29(28):3791-7.

檢索‎: PubMed 21860000

DOI碼‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 （開啟新視窗）

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. （開啟新視窗）

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

來源‎: Cancer 2012;118(3):848-55.

檢索‎: PubMed 21751205

DOI碼‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 （開啟新視窗）

Management of anemia in cancer patients. （開啟新視窗）

Calabrich A, Katz A.

來源‎: Future Oncol 2011;7(4):507-17.

檢索‎: PubMed 21463140

DOI碼‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 （開啟新視窗）

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. （開啟新視窗）

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

來源‎: BJU Int 2011;108(10):1582-7.

檢索‎: PubMed 21443653

DOI碼‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 （開啟新視窗）

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. （開啟新視窗）

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

來源‎: J Clin Oncol 2010;28(13):2239-45.

檢索‎: PubMed 20368566

DOI碼‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 （開啟新視窗）

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. （開啟新視窗）

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

來源‎: Br J Cancer 2011;105(9):1267-72.

檢索‎: PubMed 21959870

DOI碼‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 （開啟新視窗）

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. （開啟新視窗）

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

來源‎: J Intern Med 2017;281(3):284-99.

檢索‎: PubMed 27926979

DOI碼‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 （開啟新視窗）

How I treat cancer-associated anemia. （開啟新視窗）

Gilreath JA, Rodgers GM

來源‎: Blood 2020;136(7):801-13.

檢索‎: PubMed 32556170

DOI碼‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 （開啟新視窗）

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. （開啟新視窗）

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

來源‎: Eur J Haematol. 2023 110(4):354-61.

檢索‎: PubMed 36480004

DOI碼‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ （開啟新視窗）

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. （開啟新視窗）

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

來源‎: Int J Hematol 2015;102(4):401-12.

檢索‎: PubMed 26323997

DOI碼‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 （開啟新視窗）

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. （開啟新視窗）

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

來源‎: Cancer 2013;119(1):107-14.

檢索‎: PubMed 22744794

DOI碼‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 （開啟新視窗）

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. （開啟新視窗）

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

來源‎: J Natl Cancer Inst 2013;105(14):1018-26.

檢索‎: PubMed 23860204

DOI碼‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 （開啟新視窗）

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. （開啟新視窗）

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

來源‎: Cancer Sci 2013;104(4):481-5.

檢索‎: PubMed 23331490

DOI碼‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 （開啟新視窗）

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. （開啟新視窗）

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

來源‎: Br J Haematol 2019;184(2):134-60.

檢索‎: PubMed 30549002

DOI碼‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 （開啟新視窗）

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. （開啟新視窗）

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

來源‎: Support Care Cancer 2012;20(1):159-65.

檢索‎: PubMed 21359879

DOI碼‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 （開啟新視窗）

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. （開啟新視窗）

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

來源‎: Leuk Lymphoma. 2019;60(9):2324-7.

檢索‎: PubMed 30773115

DOI碼‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 （開啟新視窗）

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. （開啟新視窗）

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

來源‎: Oncologist 2010;15(9):935-43.

檢索‎: PubMed 20798194

DOI碼‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 （開啟新視窗）

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. （開啟新視窗）

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

來源‎: Lung Cancer 2012;76(3):478-85.

檢索‎: PubMed 22277104

DOI碼‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 （開啟新視窗）

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. （開啟新視窗）

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

來源‎: Eur J Haematol 2016;97(1):33-8.

檢索‎: PubMed 26341961

DOI碼‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 （開啟新視窗）

靜脈注射鐵劑

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. （開啟新視窗）

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

來源‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

檢索‎: PubMed 29471514

DOI碼‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 （開啟新視窗）

Intravenous iron in oncology. （開啟新視窗）

Auerbach M, Ballard H.

來源‎: J Natl Compr Canc Netw 2008;6(6):585-92.

檢索‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 （開啟新視窗）

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. （開啟新視窗）

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

來源‎: Int J Colorectal Dis 2016;31(3):543-51.

檢索‎: PubMed 26694926

DOI碼‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 （開啟新視窗）

How I treat cancer-associated anemia. （開啟新視窗）

Gilreath JA, Rodgers GM

來源‎: Blood 2020;136(7):801-13.

檢索‎: PubMed 32556170

DOI碼‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 （開啟新視窗）

Total dose iron dextran infusion in cancer patients: is it SaFe2+? （開啟新視窗）

Gilreath JA, Stenehjem DD, Rodgers GM.

來源‎: J Natl Compr Canc Netw 2012;10(5):669-76.

檢索‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 （開啟新視窗）

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. （開啟新視窗）

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

來源‎: Eur J Haematol. 2023 110(4):354-61.

檢索‎: PubMed 36480004

DOI碼‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ （開啟新視窗）

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. （開啟新視窗）

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

來源‎: Curr Oncol. 2023 24;30(9):7836-51.

檢索‎: PubMed 37754484

DOI碼‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ （開啟新視窗）

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. （開啟新視窗）

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

來源‎: Cochrane Database Syst Rev 2016;(2):CD009624.

檢索‎: PubMed 26845108

DOI碼‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 （開啟新視窗）

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. （開啟新視窗）

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

來源‎: World J Gastroenterol 2014;20(8):1972-85.

檢索‎: PubMed 24587673

DOI碼‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 （開啟新視窗）

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. （開啟新視窗）

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

來源‎: South Asian J Cancer. 2023 15;12(2):93-9.

檢索‎: PubMed 37969669

DOI碼‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ （開啟新視窗）

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. （開啟新視窗）

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

來源‎: J Clin Oncol 2008;26(10):1619-25.

檢索‎: PubMed 18375891

DOI碼‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 （開啟新視窗）

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. （開啟新視窗）

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

來源‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

檢索‎: PubMed 21972052

DOI碼‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 （開啟新視窗）

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. （開啟新視窗）

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

來源‎: Ann Oncol 2013;24(2):475-82.

檢索‎: PubMed 23071262

DOI碼‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 （開啟新視窗）

Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. （開啟新視窗）

Van Doren L, Steinheiser M, Boykin K, Taylor KJ, Menendez M, Auerbach M

來源‎: Am J Hematol 2024;99(7):1338-48.

檢索‎: PubMed 38282557

DOI碼‎: 10.1002/ajh.27220

https://pubmed.ncbi.nlm.nih.gov/38282557/ （開啟新視窗）

腫瘤科
貧血的管理
中文繁體（國語）
貧血的管理
https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

醫院聯絡委員會（HLC）

聯絡本地代表，他們提供免費服務，協助治療耶和華見證人的臨床醫療人員。

聯絡

醫療資訊匯總

內容包括：處理出血和貧血的無輸血醫療臨床策略，耶和華見證人在醫療事務方面的宗教和倫理立場，耶和華見證人通過全球醫院聯絡委員會系統為醫學界提供的服務。

查看下載

影片

治療耶和華見證人的臨床醫療人員可選擇的治療方法，以及需要考慮的醫學和倫理因素。

觀看影片